Comparative Pharmacology
Head-to-head clinical analysis: AZLIN versus NAFCILLIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZLIN versus NAFCILLIN SODIUM.
AZLIN vs NAFCILLIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azlin is a penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis.
Nafcillin exerts bactericidal activity by inhibiting bacterial cell wall synthesis via binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamases.
1-2 grams intravenously every 4-6 hours; total daily dose up to 12 grams for serious infections.
1-2 g IV every 4 hours; or 1-2 g IM every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 1.0–1.5 hours in adults with normal renal function; prolonged to 3–5 hours in moderate renal impairment (CrCl 10–50 mL/min) and up to 10 hours in severe renal impairment (CrCl <10 mL/min).
Approximately 0.5 hour (30 minutes) in adults with normal renal function; prolonged to 1-2 hours in neonates or severe renal impairment. Clinically relevant for dosing every 4-6 hours.
Renal excretion of unchanged drug (approximately 60-70% via glomerular filtration and tubular secretion); biliary/fecal excretion accounts for <10%.
Primarily renal (30-40% unchanged) and hepatic/biliary elimination. Approximately 10-15% excreted in bile via feces.
Category C
Category A/B
Penicillin Antibiotic
Penicillin Antibiotic